Valuation: Orgenesis Inc.

Market Cap 10L 9L 8L 7L 13.7L 9.35Cr 13.92L 93.15L 36.56L 4.69Cr 36.91L 36.1L 15Cr P/E 2023
-0.26x
P/E 2024 -0.17x
Enterprise Value 1.92Cr 1.66Cr 1.55Cr 1.42Cr 2.67Cr 182.39Cr 2.71Cr 18Cr 7.13Cr 91Cr 7.2Cr 7.04Cr 302.22Cr EV / Sales 2023
71.2x
EV / Sales 2024 27x
Free-Float
52.06%
Yield 2023 *
-
Yield 2024 -
1 day+181.25%
1 week-36.62%
Current month-36.62%
1 month+12.50%
3 months-24.37%
6 months-12.90%
Current year+200.00%
1 week 0.02
Extreme 0.02
0.45
1 month 0
Extreme 0.001
0.71
Current year 0
Extreme 0.001
0.84
1 year 0
Extreme 0.001
1
3 years 0
Extreme 0.0001
11.7
5 years 0
Extreme 0.0001
54.8
10 years 0
Extreme 0.0001
168
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 72 02/02/2012
Chief Executive Officer 57 24/12/2013
Director of Finance/CFO 51 10/03/2026
Director TitleAgeSince
Chairman 57 14/08/2014
Director/Board Member 64 08/07/2024
Director/Board Member 47 28/10/2024
Date Insider Type Main position Quantity % Market Cap.
05/03/25 Other 12,00,000 23.2142%
12/12/24 Free

Director

1,500 0.0290%
12/12/24 Free

Director

1,835 0.0355%
Change 5-day change 1-year change 3-year change Capi.($)
+181.25%-36.62%+637.70%-95.50% 34.3L
-0.14%+2.00%-18.36%-0.59% 19TCr
+1.44%+2.07%-4.47%+2.88% 11TCr
-1.40%+2.93%+15.11%+71.75% 6.12TCr
+0.65%+3.91%+37.08%+53.44% 5.44TCr
-0.12%+6.79%-5.77%-35.74% 4.82TCr
+2.08%+1.56%+10.93%-29.94% 3.2TCr
+2.09%-10.31% - - 3.09TCr
+1.57%+3.85%+47.20%-6.50% 2.49TCr
+2.45%+3.97%+0.52%+4.99% 2.31TCr
Average +18.99%+1.30%+79.99%-3.91% 5.73TCr
Weighted average by Cap. +0.53%+2.02%+0.51%+8.82%

Financials

2023 2024
Net sales 5L 5L 4L 4L 7L 5.04Cr 8L 50.23L 19.71L 2.53Cr 19.9L 19.47L 8.36Cr 10.35L 9L 8L 8L 14.43L 9.85Cr 14.65L 98.09L 38.5L 4.94Cr 38.87L 38.02L 16Cr
Net income -5.54Cr -4.79Cr -4.47Cr -4.1Cr -7.72Cr -526.88Cr -7.84Cr -52Cr -21Cr -264.09Cr -21Cr -20Cr -873.05Cr -4.82Cr -4.17Cr -3.89Cr -3.57Cr -6.71Cr -458.39Cr -6.82Cr -46Cr -18Cr -229.76Cr -18Cr -18Cr -759.57Cr
Net Debt 2.18Cr 1.88Cr 1.76Cr 1.61Cr 3.04Cr 207.32Cr 3.08Cr 21Cr 8.1Cr 103.92Cr 8.18Cr 8Cr 343.54Cr 1.82Cr 1.57Cr 1.47Cr 1.35Cr 2.53Cr 173.03Cr 2.57Cr 17Cr 6.76Cr 87Cr 6.83Cr 6.68Cr 286.72Cr
Logo Orgenesis Inc.
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Employees
77
Date Price Change Volume
06/26/06 $0.3500 -16.67% 100
05/26/05 $0.4200 +5.00% 100
04/26/04 $0.4000 +33.33% 110
03/26/03 $0.3000 -57.75% 951
31/26/31 $0.7100 +77.50% 100
  1. Stock Market
  2. Stocks
  3. ORGS Stock